Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Gross Profit (2016 - 2025)

Historic Gross Profit for Usana Health Sciences (USNA) over the last 16 years, with Q3 2025 value amounting to $164.9 million.

  • Usana Health Sciences' Gross Profit rose 241.73% to $164.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $722.7 million, marking a year-over-year increase of 368.41%. This contributed to the annual value of $693.3 million for FY2024, which is 685.54% down from last year.
  • As of Q3 2025, Usana Health Sciences' Gross Profit stood at $164.9 million, which was up 241.73% from $185.7 million recorded in Q2 2025.
  • Usana Health Sciences' Gross Profit's 5-year high stood at $294.5 million during Q1 2022, with a 5-year trough of $161.0 million in Q3 2024.
  • Over the past 5 years, Usana Health Sciences' median Gross Profit value was $186.7 million (recorded in 2022), while the average stood at $202.0 million.
  • As far as peak fluctuations go, Usana Health Sciences' Gross Profit surged by 3241.86% in 2021, and later crashed by 3836.7% in 2022.
  • Over the past 5 years, Usana Health Sciences' Gross Profit (Quarter) stood at $223.6 million in 2021, then fell by 18.83% to $181.5 million in 2022, then fell by 1.52% to $178.8 million in 2023, then fell by 2.07% to $175.1 million in 2024, then fell by 5.83% to $164.9 million in 2025.
  • Its last three reported values are $164.9 million in Q3 2025, $185.7 million for Q2 2025, and $197.1 million during Q1 2025.